Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells

Lasers in Medical Science

Volumn 29, Issue 3, 2014, Pages 995-1007

  Biswas, Raktim ^a   Chung, Phil Sang ^a   Moon, Jeong Hwan ^a   Lee, Seung Ha ^a   Ahn, Jin Chul ^a  

^a Dankook University   (South Korea)

Author keywords

Anaplastic thyroid cancer; Apoptosis; Carboplatin; Caspases; PDT; Synergism

Indexed keywords

APOPTOSIS INDUCING FACTOR; CARBOPLATIN; CASPASE 12; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; CASPASE; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; MITOCHONDRIAL PROTEIN; PROPIDIUM IODIDE;

ANAPLASTIC THYROID CANCER; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LASER; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; UPREGULATION; WESTERN BLOTTING; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; ENDOPLASMIC RETICULUM STRESS; ENZYMOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOTOCHEMOTHERAPY; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; TUMOR CELL LINE;

ANNEXIN A5; APOPTOSIS; BLOTTING, WESTERN; CARBOPLATIN; CASPASE 12; CASPASE 3; CASPASE 8; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; CYTOCHROMES C; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL PROTEINS; PHOTOCHEMOTHERAPY; PROPIDIUM; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC;

EID: 84902670020     PISSN: 02688921     EISSN: 1435604X     Source Type: Journal    
DOI: 10.1007/s10103-013-1452-9     Document Type: Article

References (50)

1. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC (2011) Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J oncol 2011:542358. doi:10.1155/2011/542358
2. Are C, Shaha A (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13(4):453-464. doi:10.1245/aso.2006.05.042
3. Ain KB (1998) Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid off j Am Thyroid Assoc 8(8):715-726
4. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC (2011) Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J oncol. doi:10.1155/2011/542358
5. Pasieka JL (2003) Anaplastic thyroid cancer. Curr opin oncol 15(1):78-83
6. Shaha AR, Ferlito A, Rinaldo A (2001) Distant metastases from thyroid and parathyroid cancer. ORL j oto-rhino-laryngol relat spec 63(4):243-249 (Pubitemid 32620177)
7. Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat rev Cancer 3(5):380-387. doi:10.1038/nrc1071 (Pubitemid 37328858)
8. Dolmans DEJGJ, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat rev Cancer 3(5):380-387 (Pubitemid 37328858)
9. Wilson BC (2002) Photodynamic therapy for cancer: principles. Can j gastroenterol 16(6):393-396
10. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90(12):889-905 (Pubitemid 28304157)
11. Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem photobiol 55(1):145-157
12. Lam M, Oleinick NL, Nieminen AL (2001) Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells. Reactive oxygen species and mitochondrial inner membrane permeabilization. J biol chem 276(50):47379-47386. doi:10.1074/jbc.M107678200
13. Brown SB, Brown EA, Walker I (2004) The present and future role of photodynamic therapy in cancer treatment. lancet oncol 5(8):497-508. doi:10.1016/S1470-2045(04)01529-3
14. Hopper C (2000) Photodynamic therapy: a clinical reality in the treatment of cancer. lancet oncol 1:212-219
15. Huang Z (2005) A review of progress in clinical photodynamic therapy. Technol cancer res treat 4(3):283-293
16. Douillard S, Lhommeau I, Olivier D, Patrice T (2010) In vitro evaluation of radachlorin sensitizer for photodynamic therapy. J photochem photobiol B Biol 98(2):128-137. doi:10.1016/j.jphotobiol.2009.11.011
17. Bae SM, Kim YW, Lee JM, Namkoong SE, Han SJ, Kim JK, Lee CH, Chun HJ, Jin HS, Ahn WS (2004) Photodynamic effects of Radachlorin on cervical cancer cells. Cancer res treat off j Korean Cancer Assoc 36(6):389-394. doi:10.4143/crt.2004. 36.6.389
18. Filonenko EV, Sokolov VV, Chissov VI, Lukyanets EA, Vorozhtsov GN (2008) Photodynamic therapy of early esophageal cancer. Photodiagn photodyn ther 5(3):187-190. doi:10.1016/j.pdpdt.2008.06.001
19. Kochneva EV, Filonenko EV, Vakulovskaya EG, Scherbakova EG, Seliverstov OV, Markichev NA, Reshetnickov AV (2010) Photosensitizer Radachlorin(R): skin cancer PDT phase II clinical trials. Photodiagn photodyn ther 7(4):258-267. doi:10.1016/j.pdpdt.2010.07.006
20. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat rev Cancer 7(8):573-584
21. Decatris MP, Sundar S, O'Byrne KJ (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer treat rev 30(1):53-81. doi:10.1016/s0305-7372(03)00139-7 (Pubitemid 38240088)
22. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl j med 345(26):1890-1900. doi:10.1056/NEJMra001375 (Pubitemid 33716564)
23. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J clin oncol off j Am Soc Clin Oncol 19(13):3210-3218 (Pubitemid 32591438)
24. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320-1329
25. Wheate NJ, Walker S, Craig GE, Oun R (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39(35):8113-8127. doi:10.1039/c0dt00292e
26. Bhuvaneswari R, Gan YY, Soo KC, Olivo M (2009) Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol cancer 8:94. doi:10.1186/1476-4598-8-94
27. Bhuvaneswari R, Yuen GY, Chee SK, Olivo M (2011) Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Lasers surg med 43(7):651-662. doi:10.1002/lsm.21109
28. Compagnin C, Mognato M, Celotti L, Canti G, Palumbo G, Reddi E (2010) Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy. Cell prolif 43(3):262-274. doi:10.1111/j.1365-2184.2010.00673.x
29. Datta SN, Allman R, Loh C, Mason M, Matthews PN (1997) Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. Br j cancer 76(3):312-317 (Pubitemid 27308080)
30. Ma LW, Moan J, Steen HB, Iani V (1995) Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma. Br j cancer 71(5):950-956
31. Ahn J-C, Biswas R, Chung P-S (2012) Combination with genistein enhances the efficacy of photodynamic therapy against human anaplastic thyroid cancer cells. Lasers surg med 44(10):840-849. doi:10. 1002/lsm.22095
32. Skirnisdottir I, Lindborg K, Sorbe B (2007) Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma. Oncol rep 18(5):1249-1256
33. Gervais R, Robinet G, Clement-Duchene C, Denis F, Kouri CE, Martin P, Chouaki N, Bourayou N, Morere JF (2013) Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Lung Cancer. doi:10.1016/j.lungcan.2013. 01.008
34. Fury MG, Sherman E, Ho A, Katabi N, Sima C, Kelly KW, Nwankwo O, Haque S, Pfister DG (2012) A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer chemother pharmacol 70(1):121-128. doi:10.1007/s00280-012-1894-y
35. Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, Pogue BW, Finkelstein D, Hasan T (2010) Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer res 70(22):9319-9328. doi:10.1158/0008-5472.CAN-10-1783
36. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer res 70(2):440-446. doi:10.1158/0008-5472. CAN-09-1947
37. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol rev 58(3):621-681. doi:10.1124/pr.58.3.10
38. Pozarowski P, Darzynkiewicz Z (2004)Analysis of cell cycle by flow cytometry. Methods Mol Biol 281:301-311. doi:10.1385/1-59259-811-0:301
39. Elisei R (2012) Anaplastic thyroid cancer therapy: dream or reality? Endocrine. doi:10.1007/s12020-012-9785-x
40. Yu GP, Li JC, Branovan D, McCormick S, Schantz SP (2010) Thyroid cancer incidence and survival in the National Cancer Institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid off j Am Thyroid Assoc 20(5):465-473. doi:10.1089/thy.2008.0281
41. Rajeswaran A, Trojan A, Burnand B, Giannelli M (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59(1):1-11. doi:10.1016/j.lungcan. 2007.07.012
42. Ofner JG, Schlogl H, Kostron H (1996) Unusual adverse reaction in a patient sensitized with Photosan 3. J photochem photobiol B Biol 36(2):183-184
43. Chen H-H, Chen T-W, Lin H (2010) Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptor α-regulated heme oxygenase-1. Mol Pharmacol 78(1):36-45. doi:10.1124/mol.109.061101
44. Sharma A, Bhat MK (2011) Enhancement of carboplatin- and quercetin-induced cell death by roscovitine is Akt dependent and p53 independent in hepatoma cells. Integr cancer ther 10(4):NP4-NP14. doi:10.1177/ 1534735411423922
45. Bevis KS, McNally LR, Sellers JC, Della Manna D, Londono Joshi A, Amm H, Straughn JM Jr, Buchsbaum DJ (2011) Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol oncol 121(1):193-199. doi:10.1016/j.ygyno.2010.11.046
46. Panzarini E, Inguscio V, Dini L (2011) Timing the multiple cell death pathways initiated by Rose Bengal acetate photodynamic therapy. Cell death dis 2:e169. doi:10.1038/cddis.2011.51
47. Granville DJ, Carthy CM, Jiang H, Shore GC, McManus BM, Hunt DWC (1998) Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett 437(1-2):5-10. doi:10.1016/S0014-5793(98)01193-4 (Pubitemid 28498230)
48. Singh S, Chhipa RR, Vijayakumar MV, Bhat MK (2006) DNA damaging drugs-induced down-regulation of Bcl-2 is essential for induction of apoptosis in high-risk HPV-positive HEp-2 and KB cells. Cancer lett 236(2):213-221. doi:10.1016/j.canlet.2005.05.024 (Pubitemid 43732548)
49. Lee CS, Kim YJ, Jang ER, Myung SC, Kim W (2010) Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines. Eur j pharmacol 632(1-3):7-13. doi:10.1016/j.ejphar.2010.01.004
50. Robertson CA, Evans DH, Abrahamse H (2009) Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B Biol 96(1):1-8. doi:10.1016/j.jphotobiol.2009.04.001